ArticleArchives of rheumatology2025

Real-World Effectiveness and Safety of Upadacitinib in Tumor Necrosis FactorInhibitor Refractory Axial Spondyloarthritis: 52-Week Outcomes from a Single-Center Cohort.

Umut Bakay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.